Margaret L. Brandeau

Margaret L. Brandeau

Auto-generated profile, based on publicly available information

Margaret L. Brandeau

Department of Management Science and Engineering, Stanford University, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in Journal of Health Economics
Verified
Journal Article
Closed access
MBMargaret L. Brandeau
Margaret L. Brandeau
GZGregory S. Zaric
Gregory S. Zaric
ARAnke Richter
Anke Richter

2 October 2007 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DHDavid W. Hutton
David W. Hutton
DTDaniel Tan
Daniel Tan
SSSamuel K. So
Samuel K. So
MBMargaret L. Brandeau
Margaret L. Brandeau
As many as 10% of Asian and Pacific Islander adults in the United States are chronically infected with hepatitis B virus (HBV), and up to two thirds are unaware that they are infected. Without proper medical management and antiviral therapy, up to 25% of Asian and Pacific Islander persons with chronic HBV infection will die of liver disease. To assess the cost-effectiveness of 4 HBV screening and vaccination programs for Asian and Pacific Islander adults in the United States. Markov model with costs and benefits discounted at 3%. Published literature and expert opinion. Asian and Pacific Islander adults (base-case age, 40 years; sensitivity analysis conducted on ages 20 to 60 years). Lifetime. U.S. societal. A universal vaccination strategy in which all individuals are given a 3-dose vaccination series; a screen-and-treat strategy, in which individuals are given blood tests to determine whether they are chronically infected, and infected persons are monitored and treated; a screen, treat, and ring vaccinate strategy, in which all individuals are tested for chronic HBV infection and close contacts of infected persons are screened and vaccinated if needed; and a screen, treat, and vaccinate strategy, in which all individuals are tested and then vaccinated with a 3-dose series if needed. In all cases, persons found to be chronically infected are monitored and treated if indicated. Costs (2006 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness. Compared with the status quo, the screen-and-treat strategy has an incremental cost-effectiveness ratio of $36 088 per QALY gained. The screen, treat, and ring vaccinate strategy gains more QALYs than the screen and treat strategy and incurs modest incremental costs, leading to incremental cost-effectiveness of $39 903 per QALY gained compared with the screen and treat strategy. The universal vaccination and screen, treat, and vaccinate strategies were weakly dominated by the other 2 strategies. Over a wide range of variables, the incremental cost-effectiveness ratios of the screen and treat and screen, treat, and ring vaccinate strategies were less than $50 000 per QALY gained. Results depend on the accuracy of the underlying data and assumptions. The long-term effectiveness of new and future HBV treatments is uncertain. Screening programs for HBV among Asian and Pacific Islander adults are likely to be cost effective. Clinically significant benefits accrue from identifying chronically infected persons for medical management and vaccinating their close contacts. Such efforts can greatly reduce the burden of HBV-associated liver cancer and chronic liver disease in the Asian and Pacific Islander population.

25 January 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
DHDavid W. Hutton
David W. Hutton
SSSamuel K.S. So
Samuel K.S. So
MBMargaret L. Brandeau
Margaret L. Brandeau
Liver disease and liver cancer associated with childhood-acquired chronic hepatitis B are leading causes of death among adults in China. Despite expanded newborn hepatitis B vaccination programs, approximately 20% of children under age 5 years and 40% of children aged 5 to 19 years remain unprotected from hepatitis B. Although immunizing them will be beneficial, no studies have examined the cost-effectiveness of hepatitis B catch-up vaccination in an endemic country like China. We examined the cost-effectiveness of a hypothetical nationwide free hepatitis B catch-up vaccination program in China for unvaccinated children and adolescents aged 1 to 19 years. We used a Markov model for disease progression and infections. Cost variables were based on data published by the Chinese Ministry of Health, peer-reviewed Chinese and English publications, and the GAVI Alliance. We measured costs (2008 U.S. dollars and Chinese renminbi), quality-adjusted life years, and incremental cost-effectiveness from a societal perspective. Our results show that hepatitis B catch-up vaccination for children and adolescents in China is cost-saving across a range of parameters, even for adolescents aged 15 to 19 years old. We estimate that if all 150 million susceptible children under 19 were vaccinated, more than 8 million infections and 65,000 deaths due to hepatitis B would be prevented. Conclusion : The adoption of a nationwide free catch-up hepatitis B vaccination program for unvaccinated children and adolescents in China, in addition to ongoing efforts to improve birth dose and newborn vaccination coverage, will be cost-saving and can generate significant population-wide health benefits. The success of such a program in China could serve as a model for other endemic countries. (Hepatology 2009.)

21 August 2017 in Management Science
Verified
Journal Article
Closed access
DNDiana M. Negoescu
Diana M. Negoescu
KBKostas Bimpikis
Kostas Bimpikis
MBMargaret L. Brandeau
Margaret L. Brandeau
DIDan A. Iancu
Dan A. Iancu
Currently available medication for treating many chronic diseases is often effective only for a subgroup of patients, and biomarkers accurately assessing whether an individual belongs to this subgroup typically do not exist. In such settings, physicians learn about the effectiveness of a drug primarily through experimentation—i.e., by initiating treatment and monitoring the patient’s response. Precise guidelines for discontinuing treatment are often lacking or left entirely to the physician’s discretion. We introduce a framework for developing adaptive, personalized treatments for such chronic diseases. Our model is based on a continuous-time, multi-armed bandit setting where drug effectiveness is assessed by aggregating information from several channels: by continuously monitoring the state of the patient, but also by (not) observing the occurrence of particular infrequent health events, such as relapses or disease flare-ups. Recognizing that the timing and severity of such events provide critical information for treatment decisions is a key point of departure in our framework compared with typical (bandit) models used in healthcare. We show that the model can be analyzed in closed form for several settings of interest, resulting in optimal policies that are intuitive and may have practical appeal. We illustrate the effectiveness of the methodology by developing a set of efficient treatment policies for multiple sclerosis, which we then use to benchmark several existing treatment guidelines.The online appendix is available at https://doi.org/10.1287/mnsc.2017.2793 .This paper was accepted by Noah Gans, stochastic models and simulation.

1 July 2021 in Mathematical Biosciences
Verified
Journal Article
Closed access
IRIsabelle J. Rao
Isabelle J. Rao
MBMargaret L. Brandeau
Margaret L. Brandeau

1 December 2008 in Operations Research
Verified
Journal Article
Closed access
ELElisa F. Long
Elisa F. Long
NVNaveen K. Vaidya
Naveen K. Vaidya
MBMargaret L. Brandeau
Margaret L. Brandeau
A co-epidemic arises when the spread of one infectious disease stimulates the spread of another infectious disease. Recently, this has happened with human immunodeficiency virus (HIV) and tuberculosis (TB). We develop two variants of a co-epidemic model of two diseases. We calculate the basic reproduction number (R0), the disease-free equilibrium, and the quasi-disease-free equilibria, which we define as the existence of one disease along with the complete eradication of the other disease, and the co-infection equilibria for specific conditions. We determine stability criteria for the disease-free and quasi-disease-free equilibria. We present an illustrative numerical analysis of the HIV-TB co-epidemics in India that we use to explore the effects of hypothetical prevention and treatment scenarios. Our numerical analysis demonstrates that exclusively treating HIV or TB may reduce the targeted epidemic, but can subsequently exacerbate the other epidemic. Our analyses suggest that coordinated treatment efforts that include highly active antiretroviral therapy for HIV, latent TB prophylaxis, and active TB treatment may be necessary to slow the HIV-TB co-epidemic. However, treatment alone may not be sufficient to eradicate both diseases. Increased disease prevention efforts (for example, those that promote condom use) may also be needed to extinguish this co-epidemic. Our simple model of two synergistic infectious disease epidemics illustrates the importance of including the effects of each disease on the transmission and progression of the other disease.